RALLYBIO CORPORATION Accumulated Other Comprehensive Income
RALLYBIO CORPORATION (RLYB) had Accumulated Other Comprehensive Income of $0 as of 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-26
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $18.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $24.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $0.00 S-4/A · filed 2026-08-26 |
| 2026-03-31 | $1.00K S-4 · filed 2026-07-15 |
| 2025-12-31 | $18.00K S-4/A · filed 2026-08-26 |
| 2025-09-30 | $24.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $17.00K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $47.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $68.00K S-4/A · filed 2026-08-26 |
| 2024-09-30 | $169.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$71.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$71.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $15.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$208.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$272.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$61.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$214.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | -$434.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$371.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$122.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |